Lyon, France, September 19, 2006 - EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announced a series of events centered around the DGU Conference in Germany and an operations update at its recently formed German subsidiary. The DGU Conference begins September 20 in Hamburg and is the largest annual gathering of the German urology community with over 7,000 participants. EDAP is the largest provider of HIFU for localized prostate cancer, which is reimbursed under the German health plan, and continues to grow treatments at approximately 100 percent compared to the prior year. The company is presently adding marketing and education resources to further accelerate its growth to meet the expanding market opportunity in Germany.

"We are seeing increased interest already stemming from our early marketing efforts just launched in July," said Judith Johannsen, General Manager of EDAP GmbH. "These marketing efforts as well as our unmatched expertise and reputation in bringing HIFU to the German urology community will allow us to fully book the 3^rd mobile Ablatherm, delivered at the start of September, to capacity by the first quarter 2007. German interest in Ablatherm continues to grow as HIFU seeks to become a mainstream treatment choice based on its high success rate and low side effect as compared to traditional and more invasive therapies. EDAP's clinical experience is clearly attracting strong interest from urologists for both first indication and radiation failure patients."

EDAP GmbH will start its DGU program today with a press event in Hamburg. Prof. Chaussy and Dr. Thueroff from Munich and Prof. Gross from Hamburg will discuss HIFU together with a patient who was treated successfully three years ago in Munich. Invitations have been extended to more than 100 members of the German speaking press. A news article about HIFU therapy and the patient experience will be sent to 300 additional publications in Germany following the event. The patient, Eberhard Mattivi, was diagnosed at age 64 and offered only surgery or radiation. After refusing both choices based on the risks and side effects, Mattivi began a two-year research process for a preferable treatment, ultimately electing for Ablatherm-HIFU under the care of Prof. Chaussy. Today age 69, Mattivi is cancer free and retains a high quality of life thanks to HIFU's low side effects and ease of recovery.

"The description of the method convinced me. For my wife and I, it was clear. I have been cured, and I am once again enjoying my life. I owe that to HIFU and the team of doctors in Munich. I literally promote the treatment amongst my friends," said Mattivi.

The press event and other publicity and education efforts have begun in earnest since July with help from EDAP's German marketing firm. The program has recently produced stories in publications such as Sueddeutsche Zeitung, Freie Presse, Urologische Nachrichten and others in recent weeks. These publications reach more than 2 million readers. 

During the DGU Dr. Thueroff will unveil a new short film introducing HIFU therapy and its benefits to both urologists and patients. EDAP will display the Ablatherm® Integrated Imaging at booth number 47 and invites interested urologists to "Meet the Expert" sessions with specialists from Munich and Regensburg during lunch breaks on Thursday and Friday at the conference.

Last week, EDAP GmbH also sent newsletter number 7 "Ultraschall & Therapie" to 450 urology departments in Germany, Austria and Switzerland. During the DGU, EDAP GmbH will host HIFU users for a special evening to celebrate the 10^th Anniversary of HIFU in Germany, the longest running HIFU experience of any provider in the country.

"We are very pleased to see continued strong growth in Germany and early indications of the additional success we can secure through our increased marketing efforts," said Hugues de Bantel, CEO of EDAP TMS S.A. "We have committed to a significant increase in our marketing programs as the European urology community opens the opportunity to bring HIFU to the mainstream of the practice based on EDAP's clinical credibility and more than a decade of experience to support our efficacy and low side effects. These efforts are already yielding results. We believe the largest growth is still ahead and will continue to work diligently to execute the marketing programs for both patients and physicians to ensure Ablatherm-HIFU is available, reimbursed and offered for men suffering from localized prostate cancer in Europe. Germany will clearly play a key role in this process based on the growing demand for this technology by many in the German urology community, which is now opening more doors for EDAP to expand our reach in the months ahead."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.